Disc Medicine (NASDAQ:IRON) CEO Sells $2,611,950.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of Disc Medicine stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. The trade was a 12.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Disc Medicine Stock Down 1.8%

Shares of NASDAQ IRON opened at $78.84 on Friday. The company has a market cap of $3.03 billion, a P/E ratio of -11.98 and a beta of 1.00. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The stock has a fifty day moving average price of $75.60 and a 200 day moving average price of $69.92. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Research analysts anticipate that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently bought and sold shares of IRON. Arizona State Retirement System increased its holdings in shares of Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after acquiring an additional 144 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its position in shares of Disc Medicine by 3.3% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares in the last quarter. AlphaCentric Advisors LLC increased its position in shares of Disc Medicine by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after acquiring an additional 216 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Disc Medicine by 3.3% during the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after purchasing an additional 296 shares in the last quarter. Finally, State of Wyoming acquired a new stake in Disc Medicine in the second quarter valued at $25,000. Institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on IRON shares. HC Wainwright raised their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Wedbush reiterated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $90.00 target price on shares of Disc Medicine in a report on Monday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus target price of $106.50.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.